NYSE · VYNE
Healthcare · Biotechnology
$28.56
Up+$0.00 (+0.00%)
Updated Oct 7, 2026, 2:15 PM
SID Score
6.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · VYNE
1M range · 0 trading sessions · Daily adjusted prices
VYNE does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning VYNE.
Company
Market Activity
Research & News
VYNE research
Company profile and research snapshot.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 30, 2025 | HC Wainwright & Co. | Neutral | — |
| Apr 25, 2025 | HC Wainwright & Co. | Buy | — |
| Mar 6, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 19, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 14, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 27, 2026
Yarrow is advancing YB-101—a potential first-in-class anti-TSHR antibody, designed to directly disrupt the central mechanism driving both Graves’ disease ("GD") and thyroid eye disease ("TED")Dosing
zacks.com · Nov 6, 2025
VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.29 per share a year ago.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VYNE.
